Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

DOSTALOVA Simona CERNA Tereza HYNEK David KOUDELKOVA Zuzana VACULOVIČ Tomáš KOPEL Pavel HRABETA Jan HEGER Zbyněk VACULOVICOVA Markéta ECKSCHLAGER Tomáš STIBOROVA Marie ADAM Vojtěch

Year of publication 2016
Type Article in Periodical
Magazine / Source ACS APPLIED MATERIALS & INTERFACES
MU Faculty or unit

Faculty of Science

Citation
Doi http://dx.doi.org/10.1021/acsami.6b04286
Field Analytic chemistry
Keywords antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery
Description Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.